There is one clinical trial.
A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in addition to currently recommended control measures.
Description: SARS-CoV-2 disease (COVID-19) with or without symptoms at week 12 of treatment as defined by the presence of specific antibodies against the virus. Positive cases will be confirmed by PCR
Measure: COVID-19 incident cases Time: During treatment (12 weeks)Description: Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology
Measure: Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology Time: During treatment (12 weeks)Description: Severity of symptomatic SARS-CoV-2 (Covid-19) infections as defined by the following categories: Mild symptoms: malaise, fever, cough, arthralgia myalgias, Moderate symptoms: same as above plus shortness of breath Severe symptoms: clinical status requiring admission in Intensive care unit
Measure: Severity of symptomatic COVID-19 Time: During treatment (12 weeks)Description: Respiratory symptom duration in days
Measure: Respiratory symptom duration in days Time: During treatment (12 weeks)Description: Relation between treatments and symptoms duration
Measure: Relation between treatments and symptoms duration Time: During treatment (12 weeks)Description: Time course of specific IgM/IgG seroconversion
Measure: Time course of specific IgM/IgG seroconversion Time: During treatment (12 weeks)